Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jac/dkz469 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An evaluation of zanidatamab, a novel, anti-HER2 biparatopic antibody, for the treatment of biliary tract cancer.
Expert Opin Biol Ther
September 2025
Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Introduction: Zanidatamab is a humanized biparatopic IgG antibody that selectively inhibits HER2 signaling pathway by targeting two distinct epitopes in the extracellular domains II and IV of HER2. Zanidatamab received accelerated approval from the United States Food and Drug Administration for the treatment of HER2-positive (immunohistochemistry [IHC] 3+) biliary tract cancer (BTC) in November 2024. Additionally, zanidatamab received approval for the treatment of HER2 IHC 3+ BTC from the European Medicines Agency in June 2025, and from National Medical Products Administration of China in May 2025.
View Article and Find Full Text PDFComment on "Mechanical Thrombectomy for the Treatment of Iliofemoral Deep Venous Thrombosis using the ClotTriever System: A Single-Centre Experience".
Cardiovasc Intervent Radiol
August 2025
School of Law, Arka Jain University, Jamshedpur, Jharkhand, 832108, India.
Qamhawi et al. report high technical success of ClotTriever thrombectomy for iliofemoral DVT. However, reliance on short-term patency, lack of standardized stent protocols, and absence of a control arm limit conclusion.
View Article and Find Full Text PDFComment on "Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus bevacizumab".
ILIVER
December 2024
Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.
Building functional and sustainable pharmacovigilance systems: an analysis of pharmacovigilance development across high-, middle- and low-income countries.
Ther Adv Drug Saf
June 2025
Department of Medicine, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.
Background: There has been notable progress in pharmacovigilance (PV) in low- and middle-income countries (LMIC) in the last decade. However, only a few of these PV systems are fully functional, unlike in high-income countries where stringent legislation, regulations and operational guidelines have enabled the establishment of effective PV systems. The key challenges faced in LMIC include organisational inefficiencies; weak infrastructure; inconsistent and poorly enforced regulations; and inadequate financing and shortage of trained personnel.
View Article and Find Full Text PDF